Investment in Stevenage science park means new research facility by 2021

PUBLISHED: 08:30 16 August 2019

Kadans Science Partner is investing in a new Stevenage research and development facility, having bought premises from GlaxoSmithKline.

Kadans Science Partner is investing in a new Stevenage research and development facility, having bought premises from GlaxoSmithKline.

Archant

A warehouse next to the Stevenage Bioscience Catalyst in Stevenage will be transformed into a research hub as part of “an exciting new chapter” for the site.

You may also want to watch:

Kadans Science Partner has bought the 9,640sqm building on Gunnels Wood Road from GlaxoSmithKline and intends to redevelop and extend it into a multi-tenanted research and development facility by mid-2021.

The building will provide grow-on space for overflowing demand from the bioscience catalyst and Cell and Gene Therapy Catapult manufacturing centre on the science park.

Doctor Sally Ann Forsyth, chief executive of the bioscience catalyst, said: "We are delighted. There is a shared understanding of the support required to help scientific communities to thrive. The campus is an established ecosystem of companies that have raised almost £1bn of investment. This is an exciting new chapter in the expansion of this cluster."


If you value what this story gives you, please consider supporting the Comet. Click the link in the orange box above for details.

Become a supporter

This newspaper has been a central part of community life for many years. Our industry faces testing times, which is why we're asking for your support. Every contribution will help us continue to produce local journalism that makes a measurable difference to our community.

Latest from the The Comet